UA103032C2 - Селективні антитіла проти гепсидину-25 та їх застосування - Google Patents

Селективні антитіла проти гепсидину-25 та їх застосування

Info

Publication number
UA103032C2
UA103032C2 UAA201101111A UAA201101111A UA103032C2 UA 103032 C2 UA103032 C2 UA 103032C2 UA A201101111 A UAA201101111 A UA A201101111A UA A201101111 A UAA201101111 A UA A201101111A UA 103032 C2 UA103032 C2 UA 103032C2
Authority
UA
Ukraine
Prior art keywords
antibodies
hepcidin
human
useful
selective antibodies
Prior art date
Application number
UAA201101111A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Донмайєнн Дон Мун Льюнг
Пен Луань
Їнь Тань
Деррік Райан Уітчер
Піа Пауліїна Якхі
Original Assignee
Елі Ліллі Енд Компані
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Елі Ліллі Енд Компані filed Critical Елі Ліллі Енд Компані
Publication of UA103032C2 publication Critical patent/UA103032C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
UAA201101111A 2008-08-06 2009-07-29 Селективні антитіла проти гепсидину-25 та їх застосування UA103032C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8655708P 2008-08-06 2008-08-06
PCT/US2009/052044 WO2010017070A1 (en) 2008-08-06 2009-07-29 Anti-hepcidin-25 selective antibodies and uses thereof

Publications (1)

Publication Number Publication Date
UA103032C2 true UA103032C2 (uk) 2013-09-10

Family

ID=41165490

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201101111A UA103032C2 (uk) 2008-08-06 2009-07-29 Селективні антитіла проти гепсидину-25 та їх застосування

Country Status (19)

Country Link
US (1) US8609817B2 (enExample)
EP (1) EP2328931B1 (enExample)
JP (1) JP5730200B2 (enExample)
KR (1) KR101462307B1 (enExample)
CN (1) CN102112489B (enExample)
AU (1) AU2009279865B2 (enExample)
BR (1) BRPI0916624A2 (enExample)
CA (1) CA2733497C (enExample)
DK (1) DK2328931T3 (enExample)
EA (1) EA201170312A1 (enExample)
ES (1) ES2432018T3 (enExample)
IL (1) IL210643A (enExample)
MX (1) MX2011001363A (enExample)
NZ (1) NZ590863A (enExample)
PL (1) PL2328931T3 (enExample)
PT (1) PT2328931E (enExample)
UA (1) UA103032C2 (enExample)
WO (1) WO2010017070A1 (enExample)
ZA (1) ZA201100261B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102584947B (zh) * 2003-04-01 2014-03-12 国家健康医学研究所 针对丙型肝炎病毒e1e2 复合体的抗体、hcv 颗粒的组合物和药物组合物
AR069062A1 (es) * 2007-11-02 2009-12-23 Lilly Co Eli Anticuerpo anti-hepcidina
DK2606061T3 (da) 2010-08-16 2017-11-06 Pieris Pharmaceuticals Gmbh Bindingsproteiner til hepcidin
AU2012350654C1 (en) 2011-12-12 2018-05-10 Pieris Ag Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
US20140120560A1 (en) * 2012-10-26 2014-05-01 Claresa Levetan Generation of new pancreatic beta cells
US10429390B2 (en) 2012-12-18 2019-10-01 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
JP6463331B2 (ja) * 2013-03-15 2019-01-30 イントリンシック ライフサイエンシズ リミテッド ライアビリティ カンパニー 抗ヘプシジン抗体およびその使用
US9816997B2 (en) * 2013-10-03 2017-11-14 Biocare Medical, Llc Anti-SOX10 antibody systems and methods
JPWO2016027469A1 (ja) * 2014-08-21 2017-06-01 国立大学法人旭川医科大学 ヘプシジンのスプライシングバリアント並びに該バリアントを指標とした癌の診断方法
AU2015321462B2 (en) * 2014-09-22 2020-04-30 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
WO2016146587A1 (en) 2015-03-13 2016-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Hepcidin antagonists for use in the treatment of inflammation
US11692027B2 (en) 2016-09-28 2023-07-04 Board Of Regents, The University Of Texas System Antibody and protein therapeutic formulations and uses thereof
EP3559039A1 (en) 2016-12-22 2019-10-30 Università Degli Studi Magna Graecia Catanzaro A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43
WO2018234538A1 (en) 2017-06-23 2018-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Hepcidin antagonist or agonist for use in the treatment of dysregulation of mo and/or mn metabolism
CN109948371B (zh) * 2019-03-07 2021-06-25 深圳市智税链科技有限公司 为区块链节点发放身份证书的方法及相关装置
JP2022549506A (ja) 2019-09-27 2022-11-25 ディスク・メディシン・インコーポレイテッド 骨髄線維症および関連状態を処置するための方法
EP4149548A4 (en) 2020-05-13 2024-05-08 Disc Medicine, Inc. ANTI-HEMOJUVELIN ANTIBODIES (HJV) FOR THE TREATMENT OF MYELOFIBROSIS
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
JPWO2022154121A1 (enExample) * 2021-01-18 2022-07-21

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1210418B1 (en) 1999-06-02 2010-08-18 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6262247B1 (en) 1999-08-30 2001-07-17 Incyte Genomics, Inc. Polycyclic aromatic hydrocarbon induced molecules
JP4944360B2 (ja) * 2001-05-25 2012-05-30 アンスティテュ ナシオナル ド ラ サント エ ド ラ ルシュルシェ メディカル（アンセルム） 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用
CN1173737C (zh) 2002-10-21 2004-11-03 钱忠明 Hepcidin(海魄喜定)在制药中的应用
US7411048B2 (en) * 2002-11-19 2008-08-12 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
EP1578254B1 (en) 2002-11-19 2013-03-06 DRG International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
US8017737B2 (en) 2002-11-19 2011-09-13 Hasan Kulaksiz Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
US20050033029A1 (en) 2003-06-30 2005-02-10 Jin Lu Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
CA2537668A1 (en) 2003-09-29 2005-04-14 Biosite Incorporated Methods and compositions for the diagnosis of sepsis
AU2003271174A1 (en) * 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
US7723063B2 (en) * 2004-04-28 2010-05-25 Intrinsic Lifesciences Methods for measuring levels of bioactive human hepcidin
NZ560976A (en) 2005-03-11 2011-06-30 Univ Johns Hopkins Biomarkers for ovarian cancer and endometrial cancer: hepcidin
MX2009008104A (es) 2007-02-02 2009-08-07 Amgen Inc Hepcidina, antagonistas de hepcidina y metodos de uso.
GR1006896B (el) * 2007-08-24 2010-07-20 Ελληνικο Ινστιτουτο Παστερ, Μεθοδος παραγωγης μιας πεπτιδικης ορμονης
CN101903044A (zh) 2007-10-02 2010-12-01 国家健康与医学研究院 对人铁调素具有特异性的抗原结合蛋白
AR069062A1 (es) * 2007-11-02 2009-12-23 Lilly Co Eli Anticuerpo anti-hepcidina
EP2620448A1 (en) 2008-05-01 2013-07-31 Amgen Inc. Anti-hepcidin antibodies and methods of use

Also Published As

Publication number Publication date
AU2009279865B2 (en) 2013-10-10
EP2328931B1 (en) 2013-08-14
HK1156326A1 (en) 2012-06-08
PL2328931T3 (pl) 2014-01-31
CA2733497A1 (en) 2010-02-11
EP2328931A1 (en) 2011-06-08
MX2011001363A (es) 2011-04-26
PT2328931E (pt) 2013-11-07
US20110189190A1 (en) 2011-08-04
KR101462307B1 (ko) 2014-11-17
IL210643A0 (en) 2011-03-31
ES2432018T3 (es) 2013-11-29
IL210643A (en) 2015-09-24
JP2011530514A (ja) 2011-12-22
CN102112489A (zh) 2011-06-29
NZ590863A (en) 2012-10-26
BRPI0916624A2 (pt) 2015-12-01
JP5730200B2 (ja) 2015-06-03
CN102112489B (zh) 2014-05-14
AU2009279865A1 (en) 2010-02-11
KR20110031963A (ko) 2011-03-29
CA2733497C (en) 2015-06-02
US8609817B2 (en) 2013-12-17
EA201170312A1 (ru) 2012-03-30
DK2328931T3 (da) 2013-09-30
WO2010017070A1 (en) 2010-02-11
ZA201100261B (en) 2012-06-27

Similar Documents

Publication Publication Date Title
UA103032C2 (uk) Селективні антитіла проти гепсидину-25 та їх застосування
JO2828B1 (en) Anti-Hepsidine antibodies and their uses
MX2007008017A (es) Polipeptidos que se ligan a br3 y usos de los mismos.
JOP20190017A1 (ar) أجسام مضادة ترتبط مع مستقبل cgrp بشري
WO2008150946A8 (en) HUMANIZED ANTIBODIES WHICH BIND TO Aβ (1-42) GLOBULOMER AND USES THEREOF
WO2006118772A3 (en) Fcrn antibodies and uses thereof
GEP20146112B (en) Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and usage thereof
PH12015501848A1 (en) Binding agents
MY174493A (en) Binding agents
WO2005092925A3 (en) Immunoglobulin variants outside the fc region
WO2010096434A3 (en) Specific binding proteins and uses thereof
IL185754A0 (en) Novel anti-plgf antibody
TN2010000213A1 (en) Wise binding antibodies and epitopes
ZA200606516B (en) Antibodies against clostridium difficile toxins and uses thereof
WO2005110474A3 (en) HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
SG196839A1 (en) Antibodies against fcrn and use thereof
WO2006082406A3 (en) Human antibodies and proteins
WO2008008482A3 (en) Altered br3-binding polypeptides
WO2011041319A3 (en) Specific binding proteins and uses thereof
WO2009140623A3 (en) Anti-psgl-1 antibodies and methods of identification and use
WO2010014830A3 (en) Peptide therapeutics that bind vegf and methods of use thereof
WO2011053565A3 (en) Compositions and methods for detecting a tauopathy
MY159255A (en) Antigen binding proteins specific for serum amyloid p component
WO2006086799A3 (en) Prion-specific peptide reagents
UA104741C2 (uk) Моноклональні антитіла проти феропортину 1 та варіанти їх застосування